Loading clinical trials...
Loading clinical trials...
Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Inoperable Esophageal Squamous Cell Carcinoma: A Single-Arm Phase II Clinical Trial
Conditions
Interventions
Serplulimab
Tegafur-gimeracil-oteracil potassium capsule(S1)
+2 more
Locations
1
China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Start Date
May 20, 2024
Primary Completion Date
December 31, 2025
Completion Date
April 1, 2026
Last Updated
May 9, 2025
Lead Sponsor
Zhejiang Cancer Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions